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CD4+ T cells have a well-deﬁned pathogenic role in experimental autoimmune
encephalomyelitis, the rodent model of multiple sclerosis (MS), yet CD8+ T cells are com-
monly found in MS lesions. To determine whether immunological tolerance might impact
differently on CD4+ versus CD8+ T cells, we studied T cell responses in mice genetically
deﬁcient for the central nervous system (CNS) autoantigen myelin oligodendrocyte glyco-
protein (MOG) versus wild type (WT) C57BL/6 mice. We show that MOG−/− mice have
enhanced sensitivity to immunization with the immunodominant peptide of MOG (35–55),
as evidenced by increased expansion of both CD4+ and CD8+ T cell subsets. Most strik-
ingly, CD8+ T cells from MOG−/− mice responded to a novel T cell epitope which binds to
MHC class I with high afﬁnity. Despite this, MOG-responsive CD8+ T cells sourced from
either WT or MOG−/− mice failed to initiate CNS inﬂammation upon transfer to MOG-
sufﬁcient mice. In our hands, this capacity was only found in CD4+ T cells. However,
MOG−/− CD4+ cells did not show greater pathogenic activity than theirWT counterparts.
Our data indicate that, in the presence of endogenous MOG, CD8+ T cells capable of
responding to a MHC class I-restricted epitope that can be stably expressed are subject
to rigorous control through central and/or peripheral tolerance.
Keywords: CD8+ T cells, EAE, multiple sclerosis
INTRODUCTION
Given their importance in orchestrating immune responses, both
quantitatively and qualitatively, it is not surprising thatmuchwork
has focused on the actions of CD4+ T helper cell responses to
myelin autoantigens. The clear importance of HLA class II alleles
in genetic susceptibility to multiple sclerosis (MS) supports this
(Holmes et al., 2005) as do studies in experimental autoimmune
encephalomyelitis (EAE) which have overwhelmingly described
this disease being absolutely dependent on the CD4+ T cell com-
partment (Zamvil et al., 1985; Flugel et al., 1999). Furthermore, a
series of elegant studies have identiﬁed means by which immuno-
logical tolerance to MHC class II-restricted T cell epitopes of
myelin can fail, providing for the immunodominance of certain
encephalitogenic peptide antigens (reviewed in Goverman, 1999;
Anderton and Wraith, 2002).
There are some discrepancies to this paradigm, however, sug-
gesting pathogenic roles for CD8+ T cells. CD8+ cells appear
at high frequencies within CNS lesions (Babbe et al., 2000) and
parenchyma and are also enriched within the CSF of patients
with relapsing–remitting MS (Jilek et al., 2007; Malmestrom et al.,
2008). Although depleting all lymphocytes with the anti-CD52
mAb Campath 1-H can reduce clinical signs in patients with
relapsing–remitting and secondary progressive stages of MS (Coles
et al., 2006; Hirst et al., 2008), trials that selectively targeted only
CD4+ T cells showed limited beneﬁt (Racadot et al., 1993; Rum-
bach et al., 1996; van Oosten et al., 1997), suggesting that CD8+
T cells might also be an important target. Others have suggested
that transfer of myelin oligodendrocyte glycoprotein (MOG)-
reactive CD8+ T cells can also induce EAE (Sun et al., 2003; Ford
and Evavold, 2005). The pathogenic contribution of CD8+ T cells
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to MS and its animal models is therefore of increasing interest
(Mars et al., 2011).
An elegant way to assess the impact of the endogenous expres-
sion of an autoantigen upon the mature T cell repertoire is to
compare T cell responsiveness of autoantigen-deﬁcient mice with
that of their WT counterparts. In C57BL/6 mice, the immun-
odominant epitope of MOG lieswithin the 35–55peptide (pMOG;
Mendel et al., 1995). An initial study of MOG−/− mice generated
on the C57BL/6 background revealed that their T cell response
remained focused on MOG(35–55). No novel responses to pep-
tides outside this regionwere identiﬁed and that T cell populations
sourced from MOG−/− did not have enhanced encephalitogenic
activity when transferred into MOG-sufﬁcient mice (Delarasse
et al., 2003).
In the present study we sought to determine the relative
inﬂuence of immunological tolerance on the CD4+ and CD8+
autoreactive T cell repertoires, by a new comparison of WT
and MOG−/−. We were able to detect both subtle differences in
the CD4+ response and, particularly, enhanced sensitivity in the
CD8+ response to MOG in T cell populations that had matured
in absence of MOG. The effect in the CD8+ compartment was
most pronounced. As previously reported (Ford and Evavold,
2005) we found that pMOG-responsive CD8+ T cells from WT
mice responded to an epitope contained with MOG(37–46) which
poorly binds to the Db MHC class I molecule. In contrast, the
CD8+ pMOG-responsive repertoire from MOG−/− mice concen-
trated on an epitope within MOG(42–50) which binds to the Db
with greater afﬁnity. This indicates that, in the absence of endoge-
nous MOG, these MOG(42–50)-responsive CD8+ T cells escape
the normal constraints of immunological tolerance. Although this
did not manifest in enhanced pathological activity in MOG−/−
CD8+ T cells (in our hands the ability to initiate CNS inﬂamma-
tion is retained only by pMOG-responsive CD4+ cells, not CD8+
cells), it does suggest that for this region of MOG CD8+ T cells are
subject tomore rigorous control through central and/or peripheral
tolerance than their CD4+ counterparts.
MATERIALS AND METHODS
MICE AND ANTIGENS
C57BL/6J and MOG−/− mice (Delarasse et al., 2003) were bred
under speciﬁc pathogen-free conditions at the University of
Edinburgh. MOG−/− mice were also crossed with the 2D2 trans-
genic line that expresses a pMOG-responsive TCR (Bettelli et al.,
2003), kindly provided by Dr V. Kuchroo, Harvard. Six- to twelve-
week-old, sex-matched mice were used for all experiments. All
experiments were approved by the University of Edinburgh eth-
ical review panel and were conducted under United Kingdom
legislation.
The MOG(35–55; pMOG) and OVA(323–339) peptides were
obtained from the Advanced Biotechnology Centre, Imperial Col-
lege (London, UK). A panel of overlapping 15-mer peptides with
ﬁve residue shifts covering the 1–123 extracellular domain of
mouse MOG were synthesized by the laboratory of Professor
D. Wraith, University of Bristol, UK. Peptides corresponding to
37–46,41–50,and 42–50of MOGwere synthesized byGLBiochem
(Shanghai, China). The LCMV gp(33–41) was obtained from
Proimmune Ltd (Oxford, UK).
Recombinant expression and puriﬁcation of the extracellular
domain of murine MOG (rMOG), has been described previously
(Fillatreau et al., 2002).
IMMUNIZATION AND ASSESSMENT OF LYMPHOID RECALL
RESPONSES
Mice were immunized subcutaneously in each hind leg as indi-
cated either with 20 or 100μg of MOG(35–55), with 100μg of
rMOG, or with 20 μg OVA(323–339), emulsiﬁed in complete
Freund’s adjuvant (CFA) containing a total of 50 μg of heat-
killed mycobacterium tuberculosis H37Ra (Sigma, UK). Draining
inguinal and para-aortic lymph nodes (LN) and splenocytes were
sampled 10 days later. Cell suspensions from individual mice were
cultured in 96-well ﬂat-bottomed plates (BD, Oxford, UK) at
6× 105 LN cells/well, or 8 × 105 splenocytes/well, using x-Vivo
15™ serum-free medium (BioWhittaker, Maidenhead, UK) sup-
plemented with 2mM l-glutamine and 50μM 2-ME (Invitrogen
Life Technologies, Paisley, UK). Cells were stimulated in triplicate
with overlapping 15-mer peptides, or with a dose range of pMOG
for 48 h prior to addition of [3H] thymidine at 0.5μCi/well.
Thymidine incorporation was measured 18 h later using a liquid
scintillation β counter (LKB Wallac, Turku, Finland). Results are
expressed as the mean counts per minute (CPM) for each group.
Supernatants from 72 h cultures were tested for IFN-γ and IL-17
by ELISA.
For CFSE dilution assays, cells were labeled with 5μM CFSE
and cultured with or without 20μM pMOG for 3 days. Cells
were counterstained with anti-CD4 and anti-CD8 prior to ﬂow
cytometric analysis.
INDUCTION AND ASSESSMENT OF EAE
Active EAE was induced by immunization with 100μg pMOG as
above.Mice also received 200 ng pertussis toxin (Health Protection
Agency,Dorset,UK) i.p. in 500 μl PBS on the day of immunization
and 2 days later.
Passive EAE was induced using a previously described proto-
col (O’Connor et al., 2007). Donor mice were immunized with
100μg pMOG as above. Eight days later draining LN cells were
prepared and cultured at 4× 106 cells/ml with 10 μg/ml pMOG,
0.5 ng/ml IL-2, 25 ng/ml rIL-12 (R&D Systems), and 25 ng/ml rIL-
18 (MBP International). After 48 h, the ﬁnal concentration of IL-2
was increased to 2 ng/ml for a further 24 h. In some experiments
CD4+ cells were selected using magnetic anti-CD4 microbeads.
CD8+ cells were selected by removal of CD19+ and CD4+ cells
from the cell suspension by magnetic anti-CD4 and anti-CD19
microbeads (Miltenyi Biotec, Germany). Both CD4+ and CD8+
populations were further enriched by FACS sorting to ensure high
purity (96± 2%). Host mice received an intravenous injection of
cells (unsorted cells, sorted CD4+ or CD8+ cells, or mixed popu-
lations, as indicated). Mice also received 200 ng pertussis toxin i.p.
in 500μl PBS on the same day as cell transfer.
Clinical signs of EAE were assessed daily with the following
scoring system: 0,no signs; 1,ﬂaccid tail; 2, impaired righting reﬂex
and/or gait; 3, partial hind limb paralysis; 4, complete hind limb
paralysis; 5, hind limb paralysis and partial front limb paralysis; 6,
moribund or dead.
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FLOW CYTOMETRIC ANALYSIS
For phenotypic analysis of T cell populations, cells were stained
with anti-CD3, anti-CD4, and anti-CD8 (all from eBioscience,
USA). T cells were gated on live, single CD3+ T cells and the fre-
quency of CD4+ or CD8+ T cells assessed. Data was acquired on
a BD LSR II or LSR Fortessa (BD Biosciences, USA) and analyzed
with Flowjo analysis software (Treestar, USA).
MOG-REACTIVE T CELL LINES
Lymph node cells were harvested from mice immunized 10 days
previously as indicated. CD4+ T cell lines were generated as previ-
ously described by repeated rounds of restimulation with pMOG
(Anderton et al., 1998; Sweenie et al., 2007). To generate pMOG-
responsiveCD8+ T cell lines,CD4+ T cells were ﬁrst depleted from
the starting LN population using magnetic anti-CD4 microbeads
(Miltenyi Biotec). The remaining cells were then cultured in the
presence of 5 μM pMOG, 10U/ml IL-2, and 10 ng/ml IL-7 for
3 days. Viable cells were recovered by density gradient centrifu-
gation and rested in 20U/ml IL-2 and 10 ng/ml IL-7 for 4 days.
Cells were subjected to three to ﬁve rounds of stimulation prior to
testing in recall assays to MOG peptides.
RMA-S Db STABILIZATION ASSAY
The RMA-S cell line was kindly provided by Professor R.
Zamoyska (University of Edinburgh). Cells were grown at 37˚C
in RPMI 1640 medium supplemented with 10% FCS, 2mM
l-glutamine, 100U/ml penicillin, 100μg/ml streptomycin, and
50μM 2-ME (Invitrogen Life Technologies). Cells were incubated
at 1.2× 106/ml with 100μM of the indicated peptide for 3 h at
37˚Cprior to counterstaining ﬁrstwith puriﬁed anti-Db, then anti-
mouse biotinylated IgG2a and then streptavidin–allophycocyanin
(BD Pharmingen). Data are expressed as the geometric MFI of
Db+ cells.
RESULTS
IN THE ABSENCE OF MOG, THE MOG-RESPONSIVE T CELL REPERTOIRE
REMAINS FOCUSED OF THE 35–55 REGION
In H-2b mice, the immunodominant region of the extracellu-
lar domain of MOG capable of stimulating T cells is contained
within the pMOG peptide (Mendel et al., 1995; Sweenie et al.,
2007). Within this peptide, the core T cell epitope has been
described as 40–48 (Mendel et al., 1996).Our ownprevious studies
using immunization with the recombinant extracellular domain
of mouse MOG (rMOG) had not identiﬁed additional naturally
processed epitopes, out with the 35–55 region, that were recog-
nized by T cells from WT C57BL/6 mice (Sweenie et al., 2007).
Other studies have probed whether MOG-deﬁcient mice are able
to mount T cell responses to additional epitopes, but those stud-
ies used immunization with synthetic peptides, rather than intact
protein (Delarasse et al., 2003). We made the assumption that, in
the presence of MOG (i.e., in WT mice), immunological tolerance
to any additional potential T cell epitopes would involve those epi-
topes that can be generated after antigen processing of the intact
MOG protein (i.e., naturally processed, rather than cryptic T cell
epitopes; Sweenie et al., 2007). With this in mind, we decided to
revisit the question of whether T cells from MOG-deﬁcient mice
can respond to additional epitopes within MOG. We immunized
MOG−/− mice with rMOG and subsequently rechallenged their
primed LN cells with overlapping peptides covering the MOG
1–123 sequence. As shown in Figure 1, these recall responses
remained absolutely focused on peptide 36–50, the only peptide
to contain the 40–48 core epitope. These data were consistent with
the previous reports on MOG−/− T cell responses using peptide
immunization protocols (Delarasse et al., 2003).We therefore have
foundno evidence thatT cells recognizing additional epitopes con-
tained in the extracellular domain of MOG (i.e., not within 35–55)
are either purged from the repertoire or rendered unresponsive in
the presence of MOG.
MOG−/− MICE ARE MORE SENSITIVE TO IMMUNE CHALLENGE WITH
MOG(35–55)
The above data indicated that in WT and MOG−/− mice, the
T cell response to rMOG was focused on the 35–55 region. To
test whether there was greater sensitivity to this region in the
absence of endogenous MOG, we immunized mice with differ-
ing doses of the pMOG peptide. As shown in Figures 2A–C, when
using an immunizing dose of 100μg of pMOG, there was the
suggestion that the resulting primed T cells from MOG−/− mice
had a greater capacity to respond to pMOG, particularly in terms
of IFN-γ release. This difference was accentuated in those mice
immunized with a lower dose of pMOG (20μg; Figures 2D–F).
In this setting, T cells from WT mice failed to proliferate and
did not produce IFN-γ or IL-17 in response to in vitro rechal-
lenge with pMOG. In contrast, T cells from MOG−/− mounted a
robust response, not discernibly weaker than the recall response
FIGURE 1 | MOG−/− T cells remain focused on MOG(35–55). MOG−/−
mice were immunized with 100μg rMOG in CFA.Ten days later, draining LN
were tested for recall responses to individual overlapping peptides as
measured by proliferation (A) or IFN-y secretion (B). Data shown are from a
representative experiment of two.
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FIGURE 2 | MOG−/− mice are highly sensitive to MOG(35–55). Mice
were immunized with either 100μg pMOG (A–C), 20μg pMOG (D–F) or
20μg OVA(323–339) (G–I) in CFA.Ten days later, splenic recall responses to
pMOG or OVA(323–339) were tested as measured by proliferation (A,D,G),
IFN-y production (B,E,H) or IL-17 production (C,F,I). Each experiment shown
in one of two experiments giving consistent results; three mice per group
were used.
seen after immunization with 100 μg pMOG,particularly in terms
of IL-17 release. This effect could not be attributed to a general,
intrinsically greater capacity of MOG−/− mice to respond to anti-
gen immunization, because responses to immunization with the
OVA(323–339) peptide were equivalent in MOG−/− andWT mice
(Figures 2G–I).
These data led us to conclude that the presence of MOG in
WT mice does, in fact, impact subtly on the ability of the T cell
repertoire to respond to the immunodominant region of MOG.
IN THE ABSENCE OF ENDOGENOUS MOG, BOTH CD4+ AND CD8+
T CELLS ARE MORE RESPONSIVE TO pMOG
The increased sensitivity that we observed inMOG−/− micemight
reﬂect the presence of more pMOG-reactive precursors than in
their WT counterparts, or that the same repertoire was present,
but in a ﬁtter condition to respond to pMOG. There have been
previous reports that immunization with pMOG is also capable of
activating Db-restricted CD8+ T cells (Sun et al., 2003). We there-
fore loaded lymphoid cells from immunized mice with CFSE prior
to culture with pMOG and subsequent assessment of the prolifer-
ation of CD4+ and CD8+ T cells by ﬂow cytometry (Figure 3A).
These assays revealed that MOG−/− samples had greater numbers
of cells that had undergone division in both the CD4+ and the
CD8+ compartments.
FIGURE 3 | Both CD4+ and CD8+T cells respond to MOG(35–55). Mice
were immunized with either 100μg or 20μg pMOG in CFA. Ten days later,
draining LN cells were stained with CFSE and cultured with or without
pMOG. CFSE dilution was analyzed on day 3 of culture in CD4+ and CD8+
T cells (A), percentages represent the frequency of gated cells that had
diluted CFSE. Results shown are one of three experiments giving
consistent results; three mice per group were used. CD4+T cell lines
developed from pMOG-immunized mice were tested for recall responses
to rMOG or pMOG (B). Naive CD4+T cells from 2D2 and 2D2MOG−/− mice
were tested for primary in vitro responses to rMOG and pMOG (C).
To test for increased responsiveness on per cell basis, we ﬁrst
generated CD4+ pMOG-responsive T cell lines from WT and
MOG−/− mice. The dose response proﬁles of these lines did not
show a greater sensitivity for T cells obtained from MOG−/− mice
(Figure 3B). Furthermore,we crossedMOG−/− micewith the 2D2
line that is transgenic for a pMOG-responsive TCR (Bettelli et al.,
2003)Naive splenocytes from thisMOG−/− line showednogreater
sensitivity to either pMOG or rMOG than their counterparts
derived form MOG-sufﬁcient 2D2 mice (Figure 3C).
IN THE ABSENCE OF ENDOGENOUS MOG, A FUNCTIONAL COHORT OF
MOG(42–50)-RESPONSIVE CD8+ T CELLS PERSISTS
No gross differences in pMOG-responsiveness were evident in the
CD4+ T cell lines derived from WT versus MOG−/− mice. We
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therefore decided to pursue potential differences in the CD8+
T cell repertoire for a number of reasons. Firstly, although depen-
dent on CD4+ T cells, the CNS lesions of mice with pMOG-
induced EAE clearly contain CD8+ cells (Figure 4). Secondly,
CD8+ T cells have been reported to have some pathogenic activity
in this model (Sun et al., 2003; Ford and Evavold, 2005; Bettini
et al., 2009). Thirdly, although the T cell epitope recognized by
CD8+ T cells from WT mice has been deﬁned as 37–46 (Ford and
Evavold, 2005), this peptide has relatively poor binding afﬁnity
for the Db MHC class-I molecule. In contrast, the adjacent 41–50
peptide was found to have greater binding afﬁnity for Db (Ford
and Evavold, 2005). We therefore developed the hypothesis that
the enhanced CD8+ T cell response to pMOG seen in MOG−/−
mice reﬂected the survival of T cells capable of responding to the
more stable Db/MOG(41–50) complex, and that these cells would
FIGURE 4 |The CNS infiltrate in pMOG-induced EAE includes CD4+ and
CD8+T cells. EAE was induced inWT mice by immunization with pMOG.
Spinal cord and brain tissue was collected 13 days later and analyzed for the
presence of CD4+ and CD8+T cell subsets within the live, singlet, CD3+
T cell gate (A). (B) Shows the frequency of CD4+ or CD8+T cells.
be purged from, or rendered unresponsive in WT mice due to the
presence of endogenous MOG.
To test this hypothesis, we ﬁrst used a Db stabilization assay to
conﬁrm the observation that the MOG(37–46) peptide is a rela-
tively poor Db binder (Figures 5A,B) RMA-S cells cultured with
this peptide, showed no elevation in their surface expression of
Db, compared with cells cultured in medium alone. Importantly,
culture with the MOG(41–50) peptide induced Db expression to
a similar level as seen with the strong Db-binding peptide, gp33–
41 of LCMV (Klavinskis et al., 1990; Hudrisier et al., 1997; Ford
and Evavold, 2005). The MOG(42–50) peptide stabilized Db to
a lesser extent than MOG(41–50) and LCMVgp(33–41), whereas
MOG(35–55) induced only a marginal shift in Db expression.
We next generated pMOG-responsive CD8+ T cell lines from
WT versus MOG−/− mice that had been immunized with pMOG.
These lines responded in a similar fashion to restimulation with
pMOG; i.e., there was no greater sensitivity apparent in the
MOG−/− T cell lines (Figure 5C). However, there was a clear dif-
ference in which of the overlapping 15-mer peptides these CD8+
T cell lines would respond to. Lines from WT mice responded to
MOG(36–50) but not MOG(41–55), indicative of a response to
the previously described 37–46 epitope. In contrast, lines gener-
ated from MOG−/− mice responded to both the MOG(36–50)
and the MOG(41–55) peptides (Figure 5D). These data could
indicate MOG−/− responses either to both 37–46 and 41–50, or
41–50 alone. We therefore pursued the response proﬁles of these
CD8+ TCL generated from pMOG-primed MOG−/− mice. Using
shorter peptides for in vitro stimulation, with found that these
CD8+ T cells responded to the MOG(42–50) peptide, but not to
the MOG(37–46) peptide (Figure 5E). Interestingly these T cells
FIGURE 5 |The CD8+T cell response in MOG−/− mice focuses on an
epitope with high affinity for Db. (A) RMA-s cells were cultured with the
indicated peptides and expression of Db assessed by ﬂow cytometry (B)
shows the geometric mean ﬂuorescence (MFI). Mice were immunized with
100μg pMOG in CFA. Ten days later, CD8+T cell lines were derived by
restimulation of CD4-depleted LN cells with pMOG. After ﬁve rounds of
stimulation, (C)T cells were tested for recall responses to pMOG or (D) to the
indicated peptides. (E) A MOG−/− CD8+T cell line was cultured with dose
ranges of the indicated peptides. Each experiment shown is one of two/three
experiments giving consistent results.
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responded to this alternative epitope as the MOG(42–50) 9-mer
rather than the MOG(41–50) 10-mer (Figure 5E) even though
the latter seemed optimal in the RMA-S Db stabilization assay
(Figures 5A,B).
Our conclusion from these studies is that MOG−/−, but not
WT mice harbor CD8+ T cells that are capable of responding
to the MOG(42–50) peptide, which binds well to the Db MHC
class I molecule. The inference therefore is that, in the presence
of endogenous MOG (in WT mice), such CD8+ T cells are either
deleted, or functionally silenced by the stable expression of their
cognate peptide-MHC complex under steady state, tolerogenic
conditions.
NEITHER WT NOR MOG−/− CD8+ T CELLS SHOW EAE INDUCING, OR
ENHANCING PROPERTIES
Previous studies have reported that pMOG-responsive CD8+
T cells generated from WT mice can transfer EAE (Sun et al.,
2003; Ford and Evavold, 2005). Our observation that MOG−/−
mice harbor CD8+ T cells recognizing a T cell epitope that has the
potential to be stably expressed in MOG-sufﬁcient mice led us to
predict that such CD8+ T cells from MOG−/− would be highly
pathogenic. We have previously reported the passive transfer of
EAE using pMOG-primed LN cells from WT mice. We ﬁnd the
most robust way of triggering pathogenic activity in these LN
populations is by exposing them to a 72-h in vitro restimulation
with pMOG in the presence of a Th1-polarizing cytokine cocktail
(IL-12+ IL-18+ IL-2; O’Connor et al., 2007). Transferring such
populations from either WT or MOG−/− mice into WT recipi-
ents produced indistinguishable clinical EAE courses (Figure 6B).
These LN populations contain CD4+ cells, CD8+ cells and also
a large non-T cell population (Figure 6A). Using traceable popu-
lations of donor cells we have always recovered a predominantly
CD4+ donor population from the inﬂamedCNSof diseased recip-
ients (O’Connor et al., 2007, 2008). However, to test (a) whether
CD8+ T cells present in these transferred populations could be
pathogenic on their own and (b) whether their pathogenic activity
might be elevated if sourced from MOG−/− mice, we transferred
CD4+ and CD8+ T populations that had been sorted (>95%
purity) following the in vitro restimulation culture. We found that
the transfer of CD4+ cells, but not CD8+, was able to reliably
achieve clinical EAE. Again, no difference in clinical picture was
apparent when using cells sourced fromWT versus MOG−/− mice
(Figure 6C).We also transferred puriﬁed T cells into RAG2−/− H-
2b mice. In these lymphopenic recipients, either WT or MOG−/−
FIGURE 6 | CD8+T cells are unable to induce EAE. Donor mice were
immunized with 100μg pMOG in CFA. Ten days later, LN cells were
restimulated with pMOG for 3 days in the presence of IL-12 and IL-18.
Cells were analyzed pre-transfer for CD4+ and CD8+T cells within the
donor population (A). Unsorted cells were injected i.v. intoWT host
mice (B). CD4+ and CD8+T cells were puriﬁed by FACS and injected into
WT hosts (C). CD8+T cells (3× 106) were transferred alongside 1× 106
unsorted cells (D) or 4× l06 injected into mice with active disease
(immunized 13 days previously) (E). Each experiment shown in one of
two/three experiments giving consistent results; three–ﬁve mice per group
were used. Figure (E) is a pool of three experiments with eight–nine mice per
group.
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CD4+ cells produced aggressive, fatal EAE within 10 days of trans-
fer, but again CD8+ cells showed no pathogenic activity (data not
shown).
These data led us to conclude that CD4+ T cells were indispens-
able for the induction of EAE in these passive transfer models.
As an aside, this is the ﬁrst time that we deﬁnitively report that
the pathogenic capacity of these stimulated LN cultures is truly
retained by the CD4+ compartment (Figure 6C).
It has been suggested previously that CD4+ T cells enter the
CNS prior to the arrival of CD8+ T cells in MOG-induced active
EAE (Sonobe et al., 2007). Thus the inability of CD8+ T cells
to induce passive disease may be related to their ability to enter
the CNS only once inﬂammation has been established by pMOG-
responsive CD4+ cells. We therefore tested whether transfer of
increased CD8+ cell numbers could exacerbate EAE induced by
unpuriﬁed “Th1” LN preparations. This was attempted in two
ways; (a) by co-transfer of additional CD8+ T cells at the time of
Th1 transfer, (b) by transfer of CD8+ T cells at the peak of clinical
EAE (we have recently shown that the transfer of a Th1 prepara-
tion at this time can exacerbate the course of EAE; Carrillo-Vico
et al., 2010). Under either protocol, transferring increased num-
bers of pMOG-stimulated CD8+ T cells, sourced from either WT
or MOG−/− mice, showed no ability to enhance EAE pathology
(Figures 6D,E).
Our conclusion from these data is that, despite our exhaus-
tive efforts, pMOG-responsive CD8+ T cells cannot initiate CNS
inﬂammation upon passive transfer and cannot exacerbate EAE
once it is underway.
DISCUSSION
The extent to which the T cell repertoire against a particular
autoantigen is molded by the presence of that autoantigen remains
an issue that is central both to immunological tolerance and to the
risk of developing an autoaggressive T cell response to that anti-
gen. The current paradigms for how autoreactive T cells can avoid
negative selectionduring thymic development have been informed
by studies of neuroantigen-responsive T cells in particular, largely
because of the array of well-characterized T cell epitopes capa-
ble of provoking EAE (Anderton et al., 1998; Goverman, 1999;
Huseby and Goverman, 2000; Anderton and Wraith, 2002). For
example, low level thymic expression of the immunodominant
139–151 peptide of proteolipid protein (PLP) in H-2S mice occurs
because the exon containing 139–151 is not included in the DM20
splice variant of PLP which is dominantly expressed in the thy-
mus (Anderson et al., 2000; Klein et al., 2000). Although myelin
basic protein (MBP) is expressed in the thymus, the immunodom-
inant encephalitogenic epitope of MBP in H-2U mice (the Ac1-9
peptide) binds very poorly to AU, generating an insufﬁcient TCR-
signal to trigger clonal deletion of Ac1-9-responsive T cells (Liu
and Wraith, 1995; Liu et al., 1995; Seamons et al., 2003). The
85–99 peptide of MBP is commonly recognized by T cells from
MS patients (this peptide can also induce EAE in H-2s mice). The
antigen processing enzyme asparaginyl endopeptidase can cleave
MBPafter the 94Asn residue, therebydestroying the 85–99 epitope,
and has been shown to be expressed in the thymus, at least provid-
ing the opportunity for destructive antigen processing (Manoury
et al., 2002).
These EAE-relevant examples highlight three ways in which
developing thymocytes can avoid encountering their cognate anti-
gen with sufﬁcient avidity to trigger their clonal deletion. Of note,
such effects would be active irrespective of the potential for AIRE-
driven ectopic expressionof the autoantigen in the thymus (Mathis
and Benoist, 2009). Of course, negative selection does stringently
remove some neuroantigen-responsive T cells. For example, in
MBP-deﬁcient H-2u mice, the immunodominant T cell epitope
of MBP lies within 121–150, not Ac1-9 as found in their MBP-
sufﬁcient counterparts. This is because the 121–150-responsive
population is purged from the T cell repertoire when MBP is
endogenously expressed (Harrington et al., 1998).
An important point is that all the above examples involveCD4+
T cell responses to neuroantigen; with good reason because, in
general, EAE is a CD4+ T cell-dependent disease. Only a few
similar studies have analyzed how autoantigen impacts on the
myelin-reactive CD8+ T cell compartment. Using MBP-deﬁcient
H-2k mice, the Goverman lab initially identiﬁed a MBP(79–87)-
responsive KK-restricted CD8+ population and showed that such
cells could be highly pathogenic when transferred to a WT H-
2k mice (Huseby et al., 2001). Evidence that CD8+ T cells have
the capacity to provoke profound CNS inﬂammation has come
from two transgenic models in which the expression of “neo-self”
antigens [OVA, or inﬂuenza hemagglutinin (HA)] was driven by
oligodendrocyte-speciﬁc promoters (Na et al., 2008; Saxena et al.,
2008). In the OVA model, crossing the antigen transgenic with the
OT-I transgenic that expressesKb-restrictedTCRrecognizingOVA
led to a spontaneous and fatal disease that was IFN-γ-dependent
(Na et al., 2008). In the HA model, disease expression required
transfer of pre-activated HA-responsive CD8+ TCR transgenic
cells, which led to oligodendrocyte loss, demyelination, and axonal
damage (Saxena et al., 2008).
In agreement with the initial published observations made
usingMOG−/− mice (Delarasse et al., 2003),we observed that both
WT and MOG−/− mice respond only to the same immunodom-
inant region within recombinant mouse MOG, MOG(35–55).
Given the profound differences seen in some earlier comparisons
of myelin autoantigen-deﬁcient and -sufﬁcientmice (Huseby et al.,
2001), it was somewhat surprising when Delarasse et al. (2003)
did not ﬁnd gross differences in the T cell response to MOG in
MOG−/− versus WT mice. This was born out by subsequent TCR
usage analyses of pMOG-responsive CD4+ T cells from the two
strains (Fazilleau et al., 2006).
Nevertheless, our data described here do indicate some subtle
differences that have so far gone unappreciated. Firstly, the ﬁnding
that only MOG−/− mice can mount a productive T cell response
when immunized with a low dose of pMOG suggests that these
mice do respond to MOG as a foreign antigen and, by inference,
that the T cell repertoire of WT mice has been inﬂuenced by expo-
sure to endogenous autoantigen. However, although CD4+ T cells
within the lymphoid organs of MOG−/− mice responded to low
dose immunization with pMOG, we were unable to conﬁrm that
these cells had any meaningful change in their function. pMOG-
responsiveCD4+ T cell lineswere notmore sensitive in vitro if they
were originally sourced fromMOG−/− mice.Again consistentwith
the Delarasse et al. (2003) study, the transfer of puriﬁed pMOG-
responsive CD4+ T cells provoked equivalent degrees of clinical
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disease regardless of which strain the T cells were sourced from.
Freshly isolated “naïve” pMOG-responsive T cells from 2D2 TCR
transgenic mice responded to pMOG in a similar fashion, regard-
less of whether they had developed in a mouse that did, or did not
express MOG. This latter point may be weakened by the fact that
the 2D2 TCR can cross-react with a peptide from the neuronal
autoantigen neuroﬁlament-M (Krishnamoorthy et al., 2009). It is
therefore possible that 2D2 T cell sensitivity may be controlled by
exposure to this autoantigen, irrespective of MOG expression. A
further caveat on these data is that the T cell clone from which the
2D2 TCR was originally derived came from a WT mouse that did
express MOG (Bettelli et al., 2003). Therefore, it remains possible
that this provenance imposes an “intrinsic” sensitivity limit upon
T cells that bear this TCR, which cannot be increased even when
MOG is absent throughout T cell development as was the case for
the 2D2×MOG−/− line.
The most striking feature of the MOG−/− T cell response to
pMOG was found in the CD8+ population. In WT mice, the
pMOG-responsive repertoire focuses on MOG(37–46), consistent
with previous reports (Ford and Evavold, 2005). In contrast, the
CD8+ response of MOG−/− mice was focused on the MOG(42–
50) epitope,which has a higher binding afﬁnity for Db. This would
be consistent with an avidity-based negative selection of these cells
inWTmice, althoughwe should stress that our data do not address
whether the lack of a response onWT mice was the result of physi-
cal deletion or functional inactivation.Aprevious report suggested
the presence of T cells in the repertoire of WT C57BL/6 mice that
could bind to dimeric Db loaded with the MOG(44–54) peptide
and that immunization with that peptide could produce mild clin-
ical signs of EAE with low incidence (Sun et al., 2003). However,
the nature (CD4+ versusCD8+) of theCNS inﬁltrate in thosemice
was not explored. Immunization with the MOG(40–54) peptide
gave a higher incidence of EAE, but that peptide contained the
core CD4+ epitope (40–48) so, overall, no deﬁnitive conclusions
can be drawn from that study (Sun et al., 2003).
The ultimate evidence for the importance of a suitably
restrained MOG-responsive CD8+ T cell repertoire would have
been to show enhanced pathogenic activity when transferring
CD8+ T cells from pMOG-primed MOG−/− mice, when com-
pared to their WT counterparts. However, despite extensive
attempts using a range of strategies, we came to the conclusion
that, in our hands, pMOG-responsive CD8+ T cells do not transfer
disease, even in lymphopenic hosts. Early studies reported CD8+
T cells to have suppressive function, whereby genetic ablation or
antibody-mediated depletion of CD8+ T cells resulted in exacer-
bated EAE (Koh et al., 1992; Montero et al., 2004). More recent
papers show a potential regulatory function of CD8+ T cells with
transfer of cells at the peak of disease resulting in early resolu-
tion (Lee et al., 2008; York et al., 2010). These contrast with the
reported pathogenic activity for CD8+ T cells as already discussed.
The failure of CD8+ T cells to induce EAE in our study, despite
numerous attempts with alterations in cell numbers and method
of cell isolation, is in agreement with York et al. (2010). However,
in contrast to York et al. (2010), we also found no evidence for
CD8+ regulatory function.
The CD8+ T cells we transferred secreted high quantities of
IFN-γ and TNF-α in response to pMOG (data not shown). The
populations were of high purity (>95%). In contrast highly pure
pMOG-responsive CD4+ T cells were fully pathogenic. Of note,
we were able to induce disease with as few as 1× 106 unpuri-
ﬁed, pMOG-stimulated LN preparations, which contained only
∼2× 105 CD4+ T cells. Previous reports of pathogenic CD8+
T cell transfer have not achieved the level of purity we have used
here and at least had the potential to include a contaminating
CD4+ population of that order (Sun et al., 2003; Ford and Evavold,
2005). A further complicating factor is the use of lymphopenic
hosts, which might allow the rapid expansion of a small conta-
minating CD4+ population. Importantly in the current study, we
found puriﬁed CD4+ cells, but not highly pure CD8+ cells to be
highly encephalitogenic.
Ourobservations ledus to the conclusion that,at least in the sys-
tem studied here, the processes of immunological tolerance meld
the autoreactive CD8+ T cell repertoire in a more obvious man-
ner than the CD4+ repertoire. Whether this is a general rule is
unclear, but CD8+ T cells do have certain qualities that make them
particularly dangerous as agents of autoimmune attack. Firstly,
once activated, they can act more easily as autonomous effector
cells (by killing antigen presenting stromal cells) than their CD4+
counterparts, which tend to require the destructive assistance of
intermediary innate immune cells (as highlighted by the impor-
tance of the macrophage compartment to EAE pathology; Tran
et al., 1998). Secondly, CD8+ effector cells can be exquisitely sen-
sitive to TCR stimulation by very few peptide-MHC complexes,
whereas CD4+ cell may require a higher level of antigen pre-
sentation for their reactivation in inﬂammatory sites. Thirdly, as
evidenced from peptide-MHC tetramer-based studies of humans
with viral infections, CD8+ T cells can undergo a remarkable
clonal expansion (Klenerman et al., 2002). These features all make
the need to control the degree of autoreactivity in the CD8+ T cell
compartment acute.
In summary, this study has revisited whether the endogenous
expression of MOG has an impact on immunological tolerance
and indicates that there are indeed some subtle effects not previ-
ously identiﬁed, most notably upon the pMOG-responsive CD8+
T cell repertoire. Our data show very clearly that, at least in our
hands, the ability to initiate autoimmune inﬂammation in theCNS
is entirely contained within the CD4+ T cell population. They
also highlight, however, that the mechanisms of immunological
tolerance that silence CD8+ T cells capable of responding to a
peptide-MHC complex that can be stably expressed are at least
as robust as those controlling their CD4+ T cells counterparts.
Understanding how these might break down during MS remains
a major challenge.
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